No Room for Wishful Thinking: A Clear-Cell Endometrial Cancer Case That Refused to Stay Quiet

The patient, 55 years old, a recently retired office administrator who lives on her own, entered 2023 feeling healthy. She had started menstruating at twelve, stopped at fifty-three, never used hormone-replacement therapy, and had long since raised two children to adulthood. Late that year a routine workup for new bleeding delivered a jolt: endometrial cancer.

Initial imaging suggested a single tumour measuring roughly four by four by one centimetres that had penetrated less than half the uterine muscle. Only one right-groin lymph node looked suspicious; the rest of the scan seemed clean, so clinicians presumed an early stage. In many hospitals, the final tests appear just days before the knife, and that pattern repeated here, an MRI was still pending when the pathology report and pelvic ultrasound labelled the case “low risk.” Because the label implied safety, the surgeon let the patient decide whether to keep her ovaries, and she chose to keep them.

Two days before the operation the delayed MRI confirmed the right-groin node was abnormal, yet the calendar was already set. No biopsy or needle aspiration was added; the team simply planned to remove the node during surgery. A robot-assisted procedure followed: total abdominal hysterectomy, removal of both fallopian tubes, a pelvic lymph-node dissection, and excision of the single groin node, while both ovaries remained in place.

Post-operative pathology rewrote the story in one stroke. The tumour still sat in the inner half of the myometrium, but lymph-vascular space invasion had developed. The cervix and tubes were negative, yet the right-groin node contained metastatic carcinoma with extracapsular spread, and atypical cells floated in the peritoneal washings. The formal stage vaulted to FIGO IVB, distant disease, something far more perilous than the “early stage” discussed in clinic. Chemotherapy and directed radiotherapy to the groin began immediately.

For six months the picture looked brighter: a pelvic MRI showed nothing amiss. Then, in September 2024, her CA-125 rose sharply, and by October a CT scan revealed solid masses crowding both ovaries, filling both tubes, and infiltrating the broad ligament. Ache in both groins and thighs, first dismissed as a muscle strain, proved to be tumour pain. A fresh PET-CT lit up two large, intensely metabolic ovarian lesions and scattered mesenteric deposits; CA-125 and CA-19-9 were now markedly elevated.

Reviewing the original files, the team saw warning signs they had underestimated: an aggressive groin-node metastasis, early lymph-vascular invasion, and malignant-looking peritoneal washings. They agreed on a new, far more extensive plan: an open debulking operation to remove as much tumour as possible, including both ovaries, the omentum, appendix, and any suspicious para-aortic nodes, followed by low-dose radiation to the abdominal incision to limit scarring.

Dr. Chung-Te Wang later reflected that a frozen section on the groin node—or better still, an ultrasound-guided biopsy before the first operation—would have confirmed stage IV disease and eliminated the option of preserving the ovaries. In stage IVB endometrial cancer, ovaries are a frequent harbour for spread even when they look normal.

For context, FIGO classifies endometrial cancer from stage I (confined to the uterus) through stage IV (spread to bladder, rectum, peritoneum, or distant organs). Sub-levels consider depth of muscle invasion, lymph-vascular involvement, nodal status, and extranodal deposits. Modern guidelines also call for molecular typing: POLE-mutated, mismatch-repair deficient, no-specific-molecular-profile, or p53-abnormal—as each category predicts behaviour and therapy response.

The patient now steels herself for another major surgery and the radiation that will follow. Her journey underscores a hard lesson: an apparently controlled cancer can re-emerge silently and violently, and every suspicious node deserves full investigation before decisions about organ preservation are made.

Quick Reference | FIGO Staging for Endometrial Cancer

• Stage I – confined to the uterus

  • IA1: confined to a polyp or endometrium

  • IA2: < 50 % muscle invasion, none–minimal LVSI

  • IA3: low-grade, uterine only, mild ovarian involvement

  • IB: ≥ 50 % muscle invasion, none–minimal LVSI

  • IC: aggressive histology (serous, high-grade endometrioid) yet no muscle invasion

• Stage II – cervix or significant LVSI

  • IIA: cervical stromal invasion

  • IIB: marked LVSI

  • IIC: any muscle invasion plus LVSI

• Stage III – local spread beyond uterus

  • IIIA: serosa or adnexa

  • IIIB: vagina, parametrium, or pelvic peritoneum

  • IIIC: pelvic or para-aortic nodes

• Stage IV – advanced disease

  • IVA: bladder or rectal mucosa

  • IVB: extra-pelvic peritoneum or distant metastasis

Molecular profiling (POLE-mut, dMMR, NSMP, p53-abn) is now recommended for every case.